Africa manufactures less than 2% of the medicines it consumes. Trials using loca...
Africa Trials
11
US Trials
214
Gap Ratio
19x
Nations
54
Key Finding
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
Africa manufactures less than 2% of the medicines it consumes. Trials using locally manufactured products could build pharmaceutical sovereignty, but they remain extremely rare.
The Evidence 131 words · target 156
In the governance and sovereignty of African clinical trials, does the pattern of local manufacturing capacity reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Spearman rank correlation as the primary estimand using registry metadata for each nation. Africa registered 11 relevant trials compared to 214 in the United States, revealing an 19-fold absolute gap in research volume. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Sentence Structure
Question
In the governance and sovereignty of African clinical trials, does the pattern of local manufacturing capacity reveal structural inequity in African research investment?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the Spearman rank correlation as the primary estimand using registry metadata for each nation.
Robustness
Africa registered 11 relevant trials compared to 214 in the United States, revealing an 19-fold absolute gap in research volume.
Interpretation
Temporal analysis showed 17.
Boundary
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence.
Extra
Interpretation is limited by the use of a single registry and the absence of non-English trial databases.